Clinical Trial Detail

NCT ID NCT03132467
Title Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 Antibody (Tremelimumab) in HR+/HER2- Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements yes
Sponsors M.D. Anderson Cancer Center
Indications

Her2-receptor negative breast cancer

Therapies

Durvalumab + Tremelimumab

Age Groups: adult senior

Additional content available in CKB BOOST